InsiderSignalSign in

← Insider buys

MRK

Merck & Co., Inc. · Healthcare

Insiders sold $70.7M of Merck & Co., Inc. in the last 12 months and bought none

$0Bought, 12 mo

$70.7MSold, 12 mo

$358.4BMarket cap

MRK over the last year

No insider buys filed in this year

MRK after insider buys

3 months after each buy, from the first price a copier could get.

1 buy has 3 months of prices so far. A record shows here at 3.

Congress

Members reported 127 trades in MRK since 2023.

Every filing

137 insider filings since 2016, newest first

Chirfi Guindo · EVP, Access, Policy & Comms

$1.4M−21.5%Aug 13

Jennifer Zachary · EVP and General Counsel

$10.7M−63.8%Aug 13

Richard R. Deluca · EVP&Pres, Merck Animal Heallth

$5.9M−29.1%Aug 12

Richard R. Deluca · EVP&Pres, Merck Animal Heallth

$789K−3.7%Aug 10

David R. Maraldo · EVP & Pres. MMD

$2.4M−50.7%Aug 7

David Michael Williams · EVP,Chief Info&Digital Officer

$6.8M−62.5%Aug 7

Chirfi Guindo · EVP, Access, Policy & Comms

$2.0M−24.3%Aug 7

Chirfi Guindo · CMO

$1.2M−14.0%Feb 12

Dean Y Li · EVP, Pres, MRL

$1.2M−10.0%Feb 10

Chirfi Guindo · CMO

$1.2M−12.0%Feb 9

Jennifer Zachary · EVP and General Counsel

$14.5M−64.0%Feb 9

David Michael Williams · EVP,Chief Info, Digital Office

$610K−14.0%Feb 6

Dalton E. Smart III · SVP Fin. - Global Controller

$766K−44.0%Feb 6

Johannes Jacobus Oosthuizen · Pres, U.S. Market

$1.8M−41.0%Feb 6

Caroline Litchfield · EVP and CFO

$5.0M−32.0%Feb 6

Dean Y Li · EVP, Pres, MRL

$1.8M−13.0%Feb 6

Chirfi Guindo · CMO

$2.4M−20.0%Feb 6

Richard R. Deluca · EVP, Pres, Merck Animal Heallt

$4.6M−19.0%Feb 6

Robert M Davis · Chair, CEO and President

$5.6M−10.0%Feb 6

Inge G Thulin · Director

Douglas M Baker Jr · Director

Caroline Litchfield · EVP and CFO

$4.8M−43.0%Feb 15

Robert M Davis · Chair, CEO and President

$29.5M−40.0%Feb 15

Joseph Romanelli · Pres, Human Health Int?l

$125K−5.0%Feb 14

Dean Y Li · EVP, Pres, MRL

$1.8M−24.0%Feb 12

David Michael Williams · EVP,Chief Info, Digital Office

$185K−7.0%Feb 8

Johannes Jacobus Oosthuizen · Pres, U.S. Market

$2.4M−45.0%Feb 5

Steven Mizell · EVP and CHRO

$6.4M−68.0%Feb 2

Jennifer Zachary · EVP and General Counsel

$6.3M−63.0%Feb 2

Johannes Jacobus Oosthuizen · Pres, U.S. Market

$213K−10.0%Nov 13

Richard R. Deluca · EVP, Pres, Merck Animal Heallt

$4.6M−28.0%Nov 9

Steven Mizell · EVP and CHRO

$463K−16.0%Aug 15

Steven Mizell · EVP and CHRO

$475K−14.0%Aug 4

Steven Mizell · EVP and CHRO

$6.4M−63.0%May 5

Jennifer Zachary · EVP and General Counsel

$2.3M−35.0%May 5

Rita A Karachun · SVP Fince-Global Controller

$1.9M−26.0%May 5

David Michael Williams · EVP,Chief Info, Digital Office

$877K−40.0%May 3

Richard R. Deluca · EVP, Pres, Merck Animal Heallt

$16.4M−48.0%May 2

Robert M Davis · Chair, CEO and President

$16.5M−35.0%Apr 28

Sanat Chattopadhyay · Exe V-P, Pres MMD

$15.4M−51.0%Apr 14

Joseph Romanelli · Pres, Human Health Int?l

$541K−20.0%Feb 16

Steven Mizell · EVP and CHRO

$198K−5.0%Feb 14

Steven Mizell · EVP and CHRO

$535K−13.0%Feb 10

Steven Mizell · EVP and CHRO

$462K−10.0%Feb 8

Jennifer Zachary · EVP and General Counsel

$7.8M−58.0%Feb 6

Sanat Chattopadhyay · Exe V-P, Pres MMD

$9.4M−43.0%Jan 11

Steven Mizell · EVP and CHRO

$3.5M−52.0%Nov 10

Johannes Jacobus Oosthuizen · Pres, U.S. Market

$185K−10.0%Nov 10

Robert M Davis · CEO and President

$17.2M−40.0%Nov 10

Kenneth C Frazier · Exec Chair

$23.5M−25.0%Nov 8

About Merck & Co., Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.